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ORAL CONTRIBUTIONS 
807 Novel Approaches to Cardiovascular 
807-3 
Gene Transfer and Targeting 
Monday, March 18, 2002, 9:15 a.m.-10:30 a.m. 
Georgia World Congress Center, Room 360W 
9:15 a.m. 
807-1  Intraoperative Cell-Cycle Blockade Therapy Using E2F 
Decoy for Prevention of Early Atherosclerosis in 
Coronary Bypass Vein Grafts: A Volumetric IVUS 
Subanalysis From a Prospective Randomized Double 
Blind Clinical Trial 
Mitsuvasu Terashima, Eberhard Grube, Takefumi Takahashi, Hideaki Kaneda, Thomas 
Felderhoff, Stein Iversen, Paul G. Yock, Yasuhiro Honda, Peter J. Fitzgerald, Stanford 
University, Stanford, California, Heart Center Siegburg, Siegburg, Germany. 
Baokground: Previous experimental and peripheral studies of vein grafts have shown 
that ex vivo cell-cycle blockade therapy using E2F Decoy inhibits neointimal hyperplasia 
and subsequent accelerated atherosclerosis -- the primary factors in late graft failure. 
The aim of this study was to investigate the safety and efficacy of intraoperative cell- 
cycle blockade therapy on human coronary saphenous vein bypass grafts (SVG) using 
volumetric intravascular ultrasound (IVUS). 
Methods: Decoy oligodeoxynucleotide, which binds and inactivates the pivotal cell-cycle 
transcription factor E2F, was delivered to the tissue ex vivo using a transfection device 
under completely non-distending conditions. Patients were assigned to either the treat- 
ment group (40 pM E2F decoy) or the placebo group (normal saline alone) in a prospec- 
tive, randomized, and double-blind manner. IVUS was performed on a subset of grafts 
with automated pullback at 12 months following surgery. On the cross-sectional IVUS 
image, intimal area was measured as the area of an internal hypoechoic layer between 
the lumen/intimal border and the external border of hypoechoic layer (EHL). Volumetric 
IVUS analysis was performed over a 50-ram SVG segment (10 mm to 60 mm from the tip 
of guiding catheter or SVG odfice) using Simpson's method, 
Results: Volumetric analysis was available in 65 grafts (35 E2F-decoy-treated : 30 pla- 
cebo) at 12 months. Intimal volume/5Omm and standardized intimal volume index [intimal 
volume / EHL volume, %) of the E2F group were significantly less than those of the pla- 
cebo group (intimal volume/50mm: 78.6_+45.6 mm 3 vs 114.8_+78.3 mm 3, p=0.024, and 
standardized intimal volume index: 12.5_+6.0% vs 18.4_+10.1%, p=0.005). There was no 
difference in EHL-volume/50mm between the two groups. No adverse IVUS findings 
were observed in either the E2F or the placebo groups. 
Conclusion: Volumetric IVUS analysis demonstrated that intraoperative cell-cycle block- 
ade therapy with E2F Decoy significantly suppressed early neointimal hyperplasia of 
human coronary saphenous vein grafts. This new approach may contribute to reducing 
long-term morbidity and mortality following primary coronary bypass with saphenous vein 
grafts. 
9:30 a.m. 
807-2 A Tissue Engineered Stent for Cell-Based Vascular 
Gene Transfer 
Carmelo J. Panetta. Katsumi Miyauchi, David Berry, Robert D. Simari, David R. Holmes, 
Robert S. Schwartz, Noel M. Caplice, Mayo Foundation and Clinic, Rochester, 
Minnesota, Juntendo Universi~ Tokyo, Japan. 
Background: Cell based gene transfer using a stent platform would provide significant 
advantages in terms of site-specific gene expression in the vasculature. The current 
study presents a novel stent design that allows stable in vivo transgene expression over 
a 4 week period in the vasculature. 
Methods: A fiber matrix mesh was attached to Wiktor stent end coated with fibronectin 
prior to seeding with autologous porcine smooth muscle cells (SMC), which were stably 
transduced with a plasmid encoding green fluorescence protein (GFP). Cells were grown 
to confluence in the mesh-stent prior to deployment in the porcine coronary artery. Four 
animals were studied, each receiving one autologous seeded mesh-stent. After four 
weeks, quantitative coronary angiography (QCA) was performed on each animal prior to 
sacrifice. The coronary containing the mesh-stent was removed, a section was plastic 
embedded for hemotoxylin and eosin stain and the other section for fluorescent micros- 
copy. The cells were removed from the vessel, and the number of GFP expressing cells 
were counted using flow cytometry. 
Results: Fibronectin coating of the mesh allowed 20 fold greater seeding of cells com- 
pared no coating (4.9 x 105 +/- 0.4 x 105 vs. 0.2 x 105 +/- 0.03 x 10 s cells/cm 2 mesh; 
<0.001, n=6). Stable in vivo GFP expression within the mesh stent was demonstrated 
four weeks after implantation in the porcine coronary artery by fluorescent microscopy 
and flow cytometry. No significant change in GFP positive cell number within the stent 
occurred in vivo when compared to pre-insertion analysis of a companion cell seeded 
mesh-stent (5.8 x 106 +/- 1.5 x 108 vs. 5.3 x 106 +/- 0.7 x 106 cells/cm 2 mesh; p=O.3). 
QCA revealed a maximal mean percent stenosis of 13.5 +/- 5.9 % (n=4) and histologic 
analysis revealed no apparent inflammatory infiltrate in the stented segment. 
Conclusions: This is the first in vivo study to show stable cell-based gene transfer of 
large numbers of genetically engineered cells using a stent platform, These results have 
implications for gene therapy where long term delivery of transgene is a desirable thera- 
peutic option. 
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A New Approach for Inhibition of Neointimal Lesion 
' Formation by Targeting Endothelln Expression Through 
CAAT/Enhancer Binding Protein Decoy OIIgonucleotlde 
Ute Kelkenberg, Andreas H. Wagner, Jasmin Sarhaddar, Markus Hecker, Heiko E. van 
der Leven,/-lannover Medical School Hannover, Germany, University of GSttingen, 
G~ttingen, Germany. 
Background: Deformation-induced synthesis of endothelin-1 (ET-1) may play a pivotal 
role in restenosis following percutaneous transluminal angioplasty. Thus, inhibition of ET- 
1-synthesis may be a potential promising therapeutic approach to treat restenosis. Since 
effective inhibitors of preproendothelin 1 processing to ET-1 are not available, we 
employed decoy oligonucleotides (dODN) to evaluate the effect of genetically engi- 
neered inhibition of ET-1 expression in vivo. 
Methods: We analysed carotid arteries of hypercholesterolemic rabbits after balloon 
injury and incubation with therapeutic decoy (CAAT/enhancer binding protein [C/EBP] 
consensus dODN [10 ~M, 30 min] or control decoys (C/EBP mutant dODN or buffer; n=7/ 
group). Efficiency of decoy uptake was demonstrated using Texas-red labelled decoys. 
Results: 2 days after transduction, C/EBP consensus decoy application resulted in sig- 
nificant reduction of C/EBP activity (electrophoretic mobility shift assay) and ET-1 expres- 
sion (immunohistochemistry). 28 days post balloon injury we saw a significant reduction 
of intimal thickening (computerized morphometry; intima/media-ratio: 1.13 + 0.22 [C/EBP 
consensus dODN] vs. 1.75 _+ 0.45 [controls]; mean ± SEM, n = 7, p = 0.003). Macroph- 
ages were found throughout the intima of untreated and mutant decoy-dODN-transfected 
arteries corresponding to areas of macroscopic plaque. In the C/EBP consensus decoy- 
treated animals, only isolated macrophages in areas o1 small neointimal accumulation 
and no foam cells were observed (macrophage-positive area: 10.4 % _+ 4.6 [C/EBP con- 
sensus dODN] vs. 17.2 % + 4.9 [controls]; n = 7, p = 0.04). 
Conclusion: These data indicate that intravascular application of a therapeutic decoy 
inhibiting C/EBP activity may be a feasible, safe, and effective method to reduce resteno- 
sis following balloon injury, especially under hypercholesterolemic onditions. 
10:00 a,m. 
807-4 Applicability of a Highly Eff ic ient  E lectro-Gene Transfer 
Approach for the Human Heart 
Luvi Sen, Guanggen Cui, Jack Judy, Hillel Laks, UCLA Medical Center/UCLA School of 
Medicine, Los Angeles, California. 
Electroporation is a technique involving the application of short duration, high intensity 
electric field pulses to cells. It is commonly used for in vitro gene transfeotion of cell lines 
and primary cultures, but limited work has been reported in small animal organs and tis- 
sue. Recently, we have established a novel electroporation system for ex viva gene 
transfer in large animal and human hearts. This device consisted of two electrode arrays 
directly in contact with the endocardium and epicardium in order to achieve uniform elec- 
troporation-enhanced gene transfer to the entire human heart. Using our recently devel- 
oped rabbit heteretopic functional heart transplant model, we compared the efficiency of 
ex viva intracoronary recombinant human intedeukine 10 (IL-10) gene transfer, mediated 
by either electroporation (EP), liposome (LP) or adenovirus (AD). In EP group, the burst 
of electric pulses (pulse length 5 ms, number of pulse 10, burst-interval 2 min) was 
applied to the heart during and after ex viva intracoronary gene infusion for 20 minutes. 
With 10mV/om electric field strength, transgene was homogeneously transferred into the 
whole rabbit heart in 3-10 minutes. A significant increase in IL-10 mRNA level was 
observed 2 hours and reached a peak 3 days after gene transfer. In EP group, the trans- 
gone expression in the donor left ventricular myocardium was more than 5 times higher 
compared with that in the LP group, and 1.25 fold higher than that in AD group (n=8, 
p<0.01). The increase in transgene expression was paralleled with IL-10 protein expres- 
sion. The distribution of the electroporation-mediated transgene expression was much 
more uniform than that in liposome-mediated gene transfer and adenovirus-mediated 
gene transfer. The hemodynamic and electrophysiotogic parameters recorded from the 
donor heart were the same in EP group and the control group 6 days after transplanta- 
tion. The arrhythmogenic effect was highest in AD group, less in LP group, and none in 
EP group. These results suggest that this new electroporation-mediated gene transfer is 
highly efficient and no significant cardiac adverse effect and is potentially applicable for 
ex viva or in viva gene delivery in human heart. 
10:15 a.m. 
807-5 U l t rasound in Con junct ion  With an Ultrasonic-Reflective 
Transfection Agent Enhances Gone Delivery to Cel ls  
Shaolina Huana, David D. McPherson, Robed C. MacDonald, Northwestern University, 
Chicago and Evanston, Illinois. 
Cationic liposomes have been developed that both provide ultrasonic enhancement and 
gene delivery to a target site. Low level ultrasound may enhance transfection, while 
retaining acoustic properties. 
Methods: Liposomes consisting of cationic phospholipid (O-ethyldimyristoylphosphati- 
dylcholine; EDMPC) and cholesterol were prepared according to a procedure previously 
described for anionic lipids and involving dispersion of the lipids in mannitol solution, lyo- 
philization and rehydration. The liposomes were combined with DNA to form lipoplexes, 
which only slightry diminished ultrasound reflectivity. Cultured cells in 6-well plates were 
exposed to 1-Mhz ultrasound (0.5 W/cm 2, 30 sac) in the presence of the acoustic 
lipoplexes. Quantification of transfection efficiency was by -galactosidase expression and 
that of DNA uptake by fluorescence of YOYO-rabeled -galactosidase plasmid (-gal DNA). 
Results: Uptake of DNA into vascular smooth muscle cells and transfection of BHK cells 
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were each strongly enhanced (up to 5 fold) by ultrasound exposure. (** p<0.05 vs. acous- 
tic lipid + DNA) 
Conclusions: Ultrasound in conjunction with ultrasound-reflective lipoplexes improves 
gene transfer. Acoustic liposomes conjugated to antibodies have independently been 
shown to target to vascular disease sites in vivo; thus, using ultrasound, it becomes fea- 
sible to both identify a disease site and activate a therapeutic agent in situ. 
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ORAL CONTRIBUTIONS 
814 Card iac  Gene Express ion 
Monday, March 18, 2002, 11:00 a.m.-12:15 p.m. 
Georgia World Congress Center, Room 160W 
11:00 a.rn. 
814-1 Bradycardia and Abnormal Calcium Handling in 
Transgenic Mice Overexpressing Juntin 
Mveono-Chan Cho, Jin-Sook Kwon, So-Young Choi, Tae-Jin Youn, Dong-Woon Kim, 
Chang-Soc Hong, Do-Han Kim, Chungbuk National University Hospital, Cheongju, South 
Korea, Kwangju Institute of Science and Technology, Kwangju, South Korea. 
Background; Junctin is integral membrane protein that co-localize with the ryanodine 
receptor (RyR), calsequestrin and triadin at the junctional SR membrane in cardiac and 
skeletal muscle. 
Methods; To investigate physiological role of junctin in excitation-contraction coupling, 
transgenic mice overexpressing junctin were developed. 
Results; Transgenic (TG) mice exhibited 14-fold higher levels of junctin in myocardium 
and survived into adulthood, but developed cardiac hypertrophy of variable severity from 
mild increase in mass to generalized cardiac hypertrophy with early death. Junctin TG 
mice had a normal LV end-diastolic dimension and systolic function on echocardio- 
graphy. In two transgenic lines (Lines t 22 and 129) having higher junctin expression, RV 
failure with marked RA and RV dilatation developed and subsequently resulted into early 
death. In junctin TG mice, ANF expression was increased in all cardiac chambers. Micro- 
scopic examination of the TG heart revealed general cardiac hypertrophy with increased 
collagen contents and thrombus in both atria. Ultrastructural analysis demonstrated irreg- 
ular Z-band intervals, loss of mitochondrial membrane or cisternae. The HR (375±51/ 
rain) of the TG mice was less than that (440±61/min) of their littermates (p<0.01). Brady- 
cardia with intermittent ventdcular premature beats was observed in the young TG mice. 
In TG heart, the expression levels of triadin and ryanodine receptor were significantly 
decreased and protein level of dihydropyridine receptor was increased without significant 
changes in other E-C coupling proteins. The capacitance of TG cardiomyocytes 
(313.8±15.2pF) was similar to that (324.6±16.7pF) of wild-type. Ca 2+ release from SR in 
single cardiomyocytes did not appear to be altered in TG mice. On the other hand, L-type 
Ca 2+ current density in the ventricular cardiomyocyte was significantly increased, which 
could cause the observed prolonged action potential durations and bradycardia. 
Conclusion; These results suggest that regulation of junctin expression must play an 
important role in proper heart function. 
11:15 a.m. 
814-2 Gene Therapy Using a Novel Method of Delivery: 
Continuous Perimuscular Infiltration 
Ariel Roouin, Samy Nitecki, Irit Rubinstein, Edmond Sabo, Zaid A. Abassi, Meira Frank, 
Nina S. Levy, Orit Lache, Aharon Hoffman, Andrew P. Levy, Rambam Medical Center, 
Haifa, Israel, Technion - israel Institute of Technology, Haifa, Israel. 
Introduction: Gene therapy with angiogenic cytokines that induce the development of 
collaterals in ischemic tissue are usually given by a single intra-artedal or intra-muscular 
(IM) injection. Naked DNA has no immunological side effects however its infectivity is 
usually low. Our aim was to evaluate the usefulness of a new method for gene therapy -
continuous infiltration of naked-DNA and compare it with IM in augmenting collateral for- 
mation and tissue perfusion in a mouse unilateral ischemic hindlimb model. 
Methods: The left lilac artery of C57 mice was ligated in two pieces and cut. An osmotic 
infusion pump containing a placebo or VEGF in different concentrations was implanted 
intra-abdominaly and the outlet tube from the pump fenestrated and tunneled into the left 
quadriceps muscle. This novel system delivers perimusculary the tested drug in a con- 
stant rate of 1 i~L/hour for 7 days. Ischemic (left)/normal (dght) limb blood flow was mea- 
sured using a laser Doppler blood flow meter and was monitored every 3-days. 
Results: The flow restoration using continuous infiltration was faster and more complete 
than with IM injection (p<0.05). For the continuous infiltration group; auto-amputation due 
to severe ischemia was observed only in the placebo group (33% Vs. 0%). VEGF 
resulted in a faster and more complete restoration of blood flow. Furthermore, the resto- 
ration of blood flow by VEGF was dose dependent. By day 7 the blood flow was almost 
complete for the group treated with 500 pg VEGF, while in the placebo group the flow 
returned to normal only after 21 days (p<0.05). Vessel density using smooth muscle ectin 
(arteriogenesis) and factor VIII (angiogenesis) were higher in the VEGF continuous infil- 
tration group. PCR demonstrated the plasmid infiltrated only in the ischemic leg and in 
the liver 
Conclusions: Our results demonstrate that using a continuous perimuscular infiltration 
for 7-days of naked-DNA encoding VEGF via an osmotic pump is associated with muscle 
and limb salvage due to the rapid and successful restoration of blood flow. The flow rate 
restoration was faster and more comlete than the traditional IM method. This method 
could serve as another option for gene therapy delivery. 
11:30 a.m, 
814-3 Distinct Expression Patterns of Connexin$ in the 
Chambers and Conduction System of the Human Fetal 
Heart 
Rivaz A. Kaba. Steven R. Coppen, Emmanuel Dupont, Jeremy N. Skepper, Suzy Elneil, 
Magdi H. Yecoub, Stephen Rothery, Nicholas J. Severs, National Heart & Lung Institute, 
imperial College, London, United Kingdom, University of Cambridge, Cambridge, United 
Kingdom. 
Background: Gap junctions have been shown to play an important role in the structural 
and electrophysiological development of the mouse heart. This study was undertaken to 
determine the specific expression pattern of three connexin isotypes, conoexins 40, 43 
and 45, in the atria and ventricles of the 9-week human fetal heart. Methods: Five heads 
of 9-week old fetuses obtained from surgical termination of pregnancy were rapidly fro- 
zen for examination by immunocytochemistry and Western blotting. Confocal microscopy 
was employed to study the distribution of immunolabeled connexins 40, 43 and 45 in the 
atria and ventricles. Double labeling techniques were applied to examine the spatial rela- 
tionship of expression of pairs of connexin isotypes. Hearts were also analyzed by West- 
em blotting for connexins 43 and 40 after separating the atda and the ventricles. Results: 
The predominant connexin in the 9-week human fetal atrium was connexin40, which was 
co-expressed with lower levels of connexin45. Connexin43 (the major human adult car- 
diac connexin) was virtually undetectable in the atria. In the ventricles, by contrast, 
connexin43 predominated while connexin45 was found at similar levels to those in the 
atria. Connexin40 was far less abundant in the ventricles than in the atria. Western blot 
analysis of connexins 43 and 40 confirmed the results obtained by the corresponding 
immunoconfocal studies. In regions of the early ventricular conduction system, from the 
commencement of the bundle branches through to the trabecular layer, all three connex- 
ins were prominently expressed. Conclusions: Our findings show that different regions 
(atria, ventricles and central conduction system) of the eady human fetal heart display 
discrete connexin profiles. Enhanced connexin expression acts as a marker of the form- 
ing ventricular conduction system as early as 9-weeks in the human fetus. The distinct 
pattern of connexin expression between the fetus and adult emphasizes the dynamic 
nature of gap junction expression during morphogenesis of the human heart. 
11:45 a.m. 
814-4 Platelet GPla (G873/873A) and GPIIbllla (leu33/33pro, 
PIA1/PIA2) Glycoprotein Receptor Polymorphisms: An 
Analysis of Functional Effects and Association With 
Risk of Premature Myocardial Infarction 
Ravi K. Sinoh. Hashmik Patel, Peter Braund, Julian Stdbling, Pat Desouza, Suzanne 
Cheng, Alison H. Goodall, Nilesh J. Samani, University of Leicester, Leicester, United 
Kingdom, Roche Molecular Systems, Alameda, California. 
Background There is controversy about the role of platelet glycoprotein receptor poly- 
morphisms, GPla (G873/873A) and GPIIbllla (leu33/33pro), in increasing risk of MI. The 
purpose of this study was to examine functional correlates of the two polymorphisms and 
investigate their role in determining risk of premature MI (<50 years), a situation in which 
any increased thrombotic tendency is likely to be most manifest. 
Methods 200 cases with a validated premature MI (mean event age 42.7±5.4 years) and 
200 age, sex and smoking status matched controls were studied. All cases were stable 
and at least 3 months beyond their thrombotic event. DNA was genotyped for the GPta 
(G873/873A) and GPIIbllla (leu33/33pro) polymorphisms by PCR. Flow cytometric analy- 
sis using fresh citrated whole blood was used to quantify GPla and GPIIbllla receptor 
expression and fibdnogen binding to the GPIIbllla receptor in response to agonist stimu- 
lation (ADP and thrombin) using CD49b, CD41 and anti-fibrinogen monoclonal antibod- 
ies respectively. Platelet volume, count and plasma fibrinogen were also measured, 
Results The GPla polymorphism demonstrated a gene dosage effect on the expression 
of the receptor on the platelet surface in both cases and controls (mean florescence 
index G/G vs G/A vs NA = 3.77_+0.18, 5.05+0.23, 5.861-0.45 and 3.98_+0.25, .27±0.27, 
6.13_+0.25 respectively, all p-values < 0.01). However, there were no significant differ- 
ences between cases and controls for genotype distributions for either the GPla (G/G vs 
G/A vs A/A = 37, 43, 20 and 41,43, 17% respectively, p = 0.68) or GPIIbllla (leu/leu vs 
leu/pro vs pro/pro = 71, 27, 1 and 68, 30, 2 respectively, p= 0.76) polymorphisms. The 
GPIIbllla polymorphism did not influence either receptor expression or fibrinogen bind- 
ing, even taking into account platelet volume, count and fibrinogen level. 
Conclusions The GPla (G873/873A) polymorphism has a significant gene dosage influ- 
ence on the expression of the receptor on the platelet surface. However, this does not 
lead to an increased risk of premature MI in subjects carrying the 873A allele. The GPllb/ 
Ilia (leu33/pro33) polymorphism does not modify either expression or activity of the 
receptor or influence risk of early MI. 
